BIOCRYST PHARMACEUTICALS INC Quarterly Weighted Average Number of Shares Outstanding, Diluted from Q2 2014 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Biocryst Pharmaceuticals Inc quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q2 2014 to Q3 2024.
  • Biocryst Pharmaceuticals Inc Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2024 was 207M shares, a 9.1% increase year-over-year.
  • Biocryst Pharmaceuticals Inc annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 192M shares, a 3.38% increase from 2022.
  • Biocryst Pharmaceuticals Inc annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 186M shares, a 3.79% increase from 2021.
  • Biocryst Pharmaceuticals Inc annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 179M shares, a 7.08% increase from 2020.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 207M +17.3M +9.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 206M +17.3M +9.15% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 206M +17.6M +9.31% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 192M +6.29M +3.38% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 190M +3.46M +1.86% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 189M +3.51M +1.89% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 189M +3.61M +1.95% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 186M +6.79M +3.79% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 186M +7.07M +3.95% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 186M +7.48M +4.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 185M +7.56M +4.26% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 179M +11.9M +7.08% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 179M +179M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 178M +178M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 177M +23.2M +15% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 167M +51.7M +44.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 177K* -110M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 162K* -110M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 154M +44M +39.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 116M +12.4M +12% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 110M +5.01M +4.75% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 110M +11.6M +11.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 110M +11.6M +11.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 103M +18.7M +22.2% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 105M +21.8M +26.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 98.8M +18.4M +22.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 98.6M +23.4M +31.2% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 84.5M +10.8M +14.6% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-13
Q3 2017 83.6M +9.84M +13.3% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 80.4M +6.72M +9.12% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 75.2M +1.57M +2.13% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 73.7M +798K +1.1% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-14
Q3 2016 73.7M +472K +0.64% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 73.7M -3.07M -3.99% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 73.6M +1.26M +1.74% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-08
Q4 2015 72.9M Oct 1, 2015 Dec 31, 2015 10-K 2018-03-12
Q3 2015 73.3M +1.46M +2.04% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-08
Q2 2015 76.8M +13.1M +20.6% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 72.3M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-09
Q3 2014 71.8M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q2 2014 63.6M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.